Overview

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-02

Target enrollment:

Participant gender:

Summary

This study specifically aims to evaluate how well GSK5733584 works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether GSK5733584 is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs

Phase:

PHASE3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG Foundation

Treatments:

Doxorubicin
Paclitaxel